These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 15483020

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88.
    Walsh PC.
    J Urol; 2005 Sep; 174(3):929. PubMed ID: 16093992
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone.
    Granfors T, Modig H, Damber JE, Tomic R.
    J Urol; 2006 Aug; 176(2):544-7. PubMed ID: 16813885
    [Abstract] [Full Text] [Related]

  • 6. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    Kroepfl D, Loewen H, Roggenbuck U, Musch M, Klevecka V.
    BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
    [Abstract] [Full Text] [Related]

  • 7. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891).
    Studer UE, Collette L, Whelan P, Albrecht W, Casselman J, de Reijke T, Knönagel H, Loidl W, Isorna S, Sundaram SK, Debois M, EORTC Genitourinary Group.
    Eur Urol; 2008 May; 53(5):941-9. PubMed ID: 18191322
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
    Studer UE, Whelan P, Wimpissinger F, Casselman J, de Reijke TM, Knönagel H, Loidl W, Isorna S, Sundaram SK, Collette L, EORTC Genitourinary Cancer Group.
    Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA.
    Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
    Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Souchon R, Stöckle M, Rübe C, Weissbach L, Althaus P, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hinke A, Hinkelbein W, Miller K.
    J Clin Oncol; 2009 Jun 20; 27(18):2924-30. PubMed ID: 19433689
    [Abstract] [Full Text] [Related]

  • 17. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy.
    Beyer DC, McKeough T, Thomas T.
    Int J Radiat Oncol Biol Phys; 2005 Apr 01; 61(5):1299-305. PubMed ID: 15817331
    [Abstract] [Full Text] [Related]

  • 18. Outcome of prostate cancer patients with initial PSA> or =20 ng/ml undergoing radical prostatectomy.
    Zwergel U, Suttmann H, Schroeder T, Siemer S, Wullich B, Kamradt J, Lehmann J, Stoeckle M.
    Eur Urol; 2007 Oct 01; 52(4):1058-65. PubMed ID: 17418938
    [Abstract] [Full Text] [Related]

  • 19. Radical prostatectomy for clinical T4 prostate cancer.
    Johnstone PA, Ward KC, Goodman M, Assikis V, Petros JA.
    Cancer; 2006 Jun 15; 106(12):2603-9. PubMed ID: 16700037
    [Abstract] [Full Text] [Related]

  • 20. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.
    Lawton CA, Winter K, Grignon D, Pilepich MV.
    J Clin Oncol; 2005 Feb 01; 23(4):800-7. PubMed ID: 15681524
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.